A Novel Compound Sclerosant: Polidocanol-Bleomycin Foam

Dermatol Surg. 2020 Dec;46(12):1712-1714. doi: 10.1097/DSS.0000000000002533.

Abstract

Background: Foam sclerotherapy is an effective treatment strategy for venous malformations. Both polidocanol (POL) and bleomycin are effective sclerosants; however, no studies have reported POL-bleomycin foam.

Objective: To introduce a method for producing POL-bleomycin foam and evaluate the stability of POL-bleomycin foam with bleomycin concentrations.

Materials and methods: Group A: 2 mL of 1% POL + 8 mL of air; Group B: 2 mL of 1% POL + 3 U bleomycin + 8 mL of air; Group C: 2 mL of 1% POL + 6 U bleomycin + 8 mL of air; Group D: 2 mL of 1% POL + 12 U bleomycin + 8 mL of air. Tessari method was used for foam generation. The foam half-life time (FHT) was used to evaluate foam stability. Five recordings were made for each group.

Results: The FHT was 148.6 ± 2.9 seconds in Group A, 148.8 ± 4.0 seconds in Group B, 148.4 ± 2.6 seconds in Group C, and 148.8 ± 1.6 seconds in Group D. The FHT in different groups showed no significant differences.

Conclusion: The POL-bleomycin foam was prepared successfully and its FHT was as long as the POL foam.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bleomycin / administration & dosage
  • Bleomycin / chemistry*
  • Drug Combinations
  • Drug Compounding / methods*
  • Drug Stability
  • Half-Life
  • Humans
  • Polidocanol / administration & dosage
  • Polidocanol / chemistry*
  • Sclerosing Solutions / administration & dosage
  • Sclerosing Solutions / chemistry*
  • Sclerotherapy / methods
  • Vascular Malformations / therapy*
  • Veins / abnormalities
  • Veins / drug effects

Substances

  • Drug Combinations
  • Sclerosing Solutions
  • Polidocanol
  • Bleomycin